Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
60 participants
OBSERVATIONAL
2023-06-01
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Salivary Proteins in Disease and Health
NCT00100204
Relationship Between Oral Findings and Salivary Factors in Sars-Cov-2 Patients
NCT05476848
Oral Manifestation in Patients With SARS-CoV2 Infection.
NCT04821986
Prevalence of Oral Mucosal Alterations in Mucocutaneous Ocular Disorders
NCT03679988
Prevalence of Oral Lesions in COVID-19 Patients
NCT04917549
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Inclusion criteria:
Adult patients aged ≥18 years.
Exclusion criteria:
* Patients with known autoimmune diseases,
* Diabetes Mellitus
* History of cancer in the region of the head and neck or previous radio and/or chemotherapy.
* History of facial nerve palsy,
* Oral and dental diseases including chronic sialadenitis or sialolithiasis.
* previous oral surgery.
Patients were divided into two equal groups each of 30 patients according to the cause of infection. Group (1) comprises 30 patients with Covid-19 infection representing the study group COVID-19 diagnosis will be based on a positive SARS-CoV-2 nasopharyngeal swab on real-time reverse transcription-polymerase chain reaction (RT-PCR) in the presence of clinical and/or radiological signs and group (2) comprises of 30 patients with non-Covid-19 infection as a control group.
All patients will be submitted to full ENT and intraoral clinical examination. We will Compare both groups as regards patients' characteristics, risk factors, etiology, symptoms, and rate of recurrence of sialadenitis.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Study group
comprises 30 patients with Covid-19 infection representing the study group COVID-19 diagnosis will be based on a positive SARS-CoV-2 nasopharyngeal swab on real-time reverse transcription-polymerase chain reaction (RT-PCR) in the presence of clinical and/or radiological signs.
No interventions assigned to this group
Control group
comprises 30 patients without a history of Covid-19 infection as a control group.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Diabetes Mellitus
* History of cancer in the region of the head and neck or previous radio and/or chemotherapy.
* History of facial nerve palsy,
* Oral and dental diseases including chronic sialadenitis or sialolithiasis.
* previous oral surgery.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Benha University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Eslam Farid Abu Shady ,MD
lecturer
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Eslam Abu Shady, MD
Role: PRINCIPAL_INVESTIGATOR
medical school
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Benha university hospitals
Banhā, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Benha university
Identifier Type: OTHER
Identifier Source: secondary_id
RC 21-4-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.